Market Cap 140.03M
Revenue (ttm) 2.04M
Net Income (ttm) -40.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,001.47%
Debt to Equity Ratio 3.09
Volume 3,854,300
Avg Vol 11,222,010
Day's Range N/A - N/A
Shares Out 222.02M
Stochastic %K 10%
Beta 2.52
Analysts Strong Sell
Price Target $1.96

Company Profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 313 9633
Address:
2525 East North Carolina Highway 54, Durham, United States
dxpython
dxpython Jul. 30 at 5:30 AM
$HUMA https://clinicaltrials.gov/study/NCT07730528?term=Humacyte&viewType=Card&rank=3
0 · Reply
Justlooking34
Justlooking34 Jul. 29 at 8:30 PM
0 · Reply
APman
APman Jul. 29 at 6:35 PM
$HUMA Another disapointing day but I bought more.
2 · Reply
teksava
teksava Jul. 29 at 4:32 PM
$HUMA there is no way this stock is only worth $.61. What in the H.E double hockey sticks is going on??
3 · Reply
Rybod30
Rybod30 Jul. 29 at 2:29 PM
$HUMA $.60 looks ready to give way, shudder to think where this might be following earnings😳…
0 · Reply
crowbaby333
crowbaby333 Jul. 29 at 12:54 PM
$HUMA The updates we will get on 8.10 will be the story. Not sure about Trauma Rev, would love to see that 1M+ but any update on Saudi negotiations (most likely extended), Israel Minitraty of Health, SBLA timing for Dialysis, the Phase 3 for PAD, we just got the IND for CABG. They got priority product by DOD, they are in ECAT, they got Veteran Affairs on board. They are laying the groundwork to be exactly where they need to be. If you look at what they say they are going to do, vs. what they do, they are hitting all thier goals. Commercialization revenue has been a drag, but only compared to your expectatoins, they never gave guidance and even in first quarters it was all about VAC acceptance rate and they told us it would be 6 months to get through VACs. The bear twats, will be the perma bear twats, and yes they need rev, but they are in a 200% better position today as they were when trauma was approved, and eventually the price catches up to the real story. Source: 125K+ shares.
3 · Reply
InspectorWick
InspectorWick Jul. 29 at 5:30 AM
$HUMA Yep. This looks like it has a story to tell. Anyone got some leads for an old gumshoe like myself?
1 · Reply
gtzmoney
gtzmoney Jul. 28 at 11:01 PM
$HUMA Blackrock owns 4 million shares ? Holy shit they will never allow a reverse split this has $1.05 a share written all over it --- We're RICH :)🤑
4 · Reply
MarketPro
MarketPro Jul. 28 at 10:47 PM
$HUMA Top Holders by Market Value:
1 · Reply
MarketPro
MarketPro Jul. 28 at 9:16 PM
$HUMA Blackrock ownership. Update:
0 · Reply
Latest News on HUMA
Humacyte announces FDA acceptance of CTEV IND application

2026-07-27T12:25:48.000Z - 2 days ago

Humacyte announces FDA acceptance of CTEV IND application


Humacyte price target lowered to $1.25 from $1.50 at TD Cowen

2026-06-17T12:32:32.000Z - 6 weeks ago

Humacyte price target lowered to $1.25 from $1.50 at TD Cowen


Humacyte Slides: Corporate presentation

Jun 16, 2026, 3:00 PM EDT - 6 weeks ago

Humacyte Slides: Corporate presentation


Humacyte Transcript: Study result

Jun 15, 2026, 5:00 PM EDT - 6 weeks ago

Humacyte Transcript: Study result


Humacyte Press release: Study result

Jun 15, 2026, 5:00 PM EDT - 6 weeks ago

Humacyte Press release: Study result


Humacyte price target raised to $4 from $3 at H.C. Wainwright

2026-06-11T13:47:07.000Z - 6 weeks ago

Humacyte price target raised to $4 from $3 at H.C. Wainwright


Humacyte 47.62M share Spot Secondary priced at $1.05

2026-06-11T01:35:07.000Z - 7 weeks ago

Humacyte 47.62M share Spot Secondary priced at $1.05


Humacyte TBA Spot Secondary; price range $1.05-$1.15

2026-06-10T22:15:08.000Z - 7 weeks ago

Humacyte TBA Spot Secondary; price range $1.05-$1.15


Humacyte announces V012 study of ATEV meets primary endpoint

2026-06-10T20:14:24.000Z - 7 weeks ago

Humacyte announces V012 study of ATEV meets primary endpoint


Humacyte announces common stock offering, no amount given

2026-06-10T20:10:11.000Z - 7 weeks ago

Humacyte announces common stock offering, no amount given


Humacyte Transcript: AGM 2026

Jun 9, 2026, 8:00 AM EDT - 7 weeks ago

Humacyte Transcript: AGM 2026


Humacyte price target raised to $2 from $1 at Benchmark

2026-06-01T11:58:24.000Z - 2 months ago

Humacyte price target raised to $2 from $1 at Benchmark


Humacyte price target raised to $1.50 from $1 at TD Cowen

2026-05-14T15:08:47.000Z - 2 months ago

Humacyte price target raised to $1.50 from $1 at TD Cowen


Humacyte reports Q1 EPS (9c), consensus (12c)

2026-05-13T13:00:50.000Z - 2 months ago

Humacyte reports Q1 EPS (9c), consensus (12c)


Humacyte Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Humacyte Earnings Call Transcript: Q1 2026


Humacyte Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Humacyte Earnings release: Q1 2026


Humacyte Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Humacyte Quarterly report: Q1 2026


Humacyte names Todd Rasmussen chief surgical officer

2026-05-12T15:32:56.000Z - 2 months ago

Humacyte names Todd Rasmussen chief surgical officer


Humacyte Transcript: KOL event

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Humacyte Transcript: KOL event


Humacyte Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Humacyte Proxy statement: Proxy filing


Humacyte Appoints Jim Mercadante as Chief Commercial Officer

Apr 22, 2026, 8:00 AM EDT - 3 months ago

Humacyte Appoints Jim Mercadante as Chief Commercial Officer


Humacyte Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Humacyte Proxy statement: Proxy filing


Humacyte price target lowered to $1.50 from $3.50 at Barclays

2026-04-08T09:30:25.000Z - 4 months ago

Humacyte price target lowered to $1.50 from $3.50 at Barclays


Humacyte Earnings Call Transcript: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 4 months ago

Humacyte Earnings Call Transcript: Q4 2025


Humacyte Annual report: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 4 months ago

Humacyte Annual report: Q4 2025


Humacyte Earnings release: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 4 months ago

Humacyte Earnings release: Q4 2025


Humacyte Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 5 months ago

Humacyte Transcript: TD Cowen 46th Annual Health Care Conference


Humacyte To Participate in Upcoming Investor Conferences

Mar 2, 2026, 8:00 AM EST - 5 months ago

Humacyte To Participate in Upcoming Investor Conferences


Humacyte Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Humacyte Earnings Call Transcript: Q3 2025


Humacyte Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Humacyte Quarterly report: Q3 2025


Humacyte Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Humacyte Earnings release: Q3 2025


Humacyte Registration statement: Registration Filing

Sep 12, 2025, 8:00 AM EDT - 11 months ago

Humacyte Registration statement: Registration Filing


Humacyte Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Humacyte Earnings Call Transcript: Q2 2025


Humacyte Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Humacyte Quarterly report: Q2 2025


Humacyte Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Humacyte Earnings release: Q2 2025


Humacyte Earnings Call Transcript: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings Call Transcript: Q1 2025


Humacyte Quarterly report: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Humacyte Quarterly report: Q1 2025


Humacyte Earnings release: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings release: Q1 2025


Humacyte Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Humacyte Proxy statement: Proxy Filing


Humacyte Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Humacyte Proxy statement: Proxy Filing


Humacyte Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Humacyte Proxy statement: Proxy Filing


Humacyte Earnings Call Transcript: Q4 2024

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings Call Transcript: Q4 2024


Humacyte Annual report: Q4 2024

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Humacyte Annual report: Q4 2024


Humacyte Earnings release: Q4 2024

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings release: Q4 2024


dxpython
dxpython Jul. 30 at 5:30 AM
$HUMA https://clinicaltrials.gov/study/NCT07730528?term=Humacyte&viewType=Card&rank=3
0 · Reply
Justlooking34
Justlooking34 Jul. 29 at 8:30 PM
0 · Reply
APman
APman Jul. 29 at 6:35 PM
$HUMA Another disapointing day but I bought more.
2 · Reply
teksava
teksava Jul. 29 at 4:32 PM
$HUMA there is no way this stock is only worth $.61. What in the H.E double hockey sticks is going on??
3 · Reply
Rybod30
Rybod30 Jul. 29 at 2:29 PM
$HUMA $.60 looks ready to give way, shudder to think where this might be following earnings😳…
0 · Reply
crowbaby333
crowbaby333 Jul. 29 at 12:54 PM
$HUMA The updates we will get on 8.10 will be the story. Not sure about Trauma Rev, would love to see that 1M+ but any update on Saudi negotiations (most likely extended), Israel Minitraty of Health, SBLA timing for Dialysis, the Phase 3 for PAD, we just got the IND for CABG. They got priority product by DOD, they are in ECAT, they got Veteran Affairs on board. They are laying the groundwork to be exactly where they need to be. If you look at what they say they are going to do, vs. what they do, they are hitting all thier goals. Commercialization revenue has been a drag, but only compared to your expectatoins, they never gave guidance and even in first quarters it was all about VAC acceptance rate and they told us it would be 6 months to get through VACs. The bear twats, will be the perma bear twats, and yes they need rev, but they are in a 200% better position today as they were when trauma was approved, and eventually the price catches up to the real story. Source: 125K+ shares.
3 · Reply
InspectorWick
InspectorWick Jul. 29 at 5:30 AM
$HUMA Yep. This looks like it has a story to tell. Anyone got some leads for an old gumshoe like myself?
1 · Reply
gtzmoney
gtzmoney Jul. 28 at 11:01 PM
$HUMA Blackrock owns 4 million shares ? Holy shit they will never allow a reverse split this has $1.05 a share written all over it --- We're RICH :)🤑
4 · Reply
MarketPro
MarketPro Jul. 28 at 10:47 PM
$HUMA Top Holders by Market Value:
1 · Reply
MarketPro
MarketPro Jul. 28 at 9:16 PM
$HUMA Blackrock ownership. Update:
0 · Reply
gtzmoney
gtzmoney Jul. 28 at 3:52 PM
$HUMA this is a pink sheet company
4 · Reply
Rybod30
Rybod30 Jul. 28 at 3:18 PM
$HUMA $.54😬…
0 · Reply
mplaster
mplaster Jul. 28 at 2:35 PM
$HUMA pathetic stock
1 · Reply
Norap58
Norap58 Jul. 28 at 10:30 AM
$HUMA Dumbass alert Classic academic work (e.g., Desai & Jain 1997) reported average 1-year buy-and-hold abnormal returns of about −11% after reverse-split announcements (and roughly −34% over three years). Stop talking BS A reverse split will confirm this stock is in a death grip and you’re sorry paid azz knows that.
1 · Reply
youdontknwjack
youdontknwjack Jul. 28 at 9:22 AM
$HUMA 🚀👩‍🚀👨‍🚀
0 · Reply
cdaviscamera
cdaviscamera Jul. 27 at 8:15 PM
$HUMA Thunderclap
0 · Reply
mplaster
mplaster Jul. 27 at 7:23 PM
$HUMA don't worry will probs be red tommorow
1 · Reply
APman
APman Jul. 27 at 6:45 PM
$HUMA This should be a buck even without the dialysis angle.
0 · Reply
izamgeoff
izamgeoff Jul. 27 at 6:32 PM
$HUMA sheltered from the market now that it’s been removed from all indexes. Failing up today lol
0 · Reply
A___A
A___A Jul. 27 at 6:31 PM
$HUMA what is this volume
0 · Reply
Merlintrader
Merlintrader Jul. 27 at 3:58 PM
$HUMA Stock Hub updated: FDA accepts the CTEV IND for a first-in-human coronary bypass study, Phase 2a planned this quarter in 10 patients - while $FMS holds a 10b5-1 plan to sell up to 5M shares through Oct 31 and the dialysis sBLA is still due in 2H26 https://www.merlintrader.com/humacyte-presentation-june2026-deepdive/
0 · Reply
rubraquercus
rubraquercus Jul. 27 at 3:45 PM
$HUMA 5 months since they hired him, now he can close a cash deal upfront with cash benchmarks and royalties for CABG sales. HUMA should not be in the sales business, someone else can sell as much or more than than they can produce...
0 · Reply